Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Tasly and SemBioSys Report Progress on their China JV

publication date: Feb 2, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tianjin Tasly Pharma and SemBioSys Genetics of Canada have received business licenses for their Tianjin-based JV, which is based on SemBioSys’ seed-based oilbody and genetic expression technology. Ultimately, the JV expects to use the technology to produce insulin for China and the rest of world. In the near-term, it will develop modernized TCM products and nutraceuticals. After that, the JV will turn its focus toward animal food additives. More details....

Stock Symbols: (SHA: 600535) (TSX: SBS)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners